Impact Investing in Cardiovascular Disease

Broadview’s mission is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.

Getting Treatments to Patients

Broadview’s mission is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.

Diversified Portfolio Across Technologies

Broadview’s mission is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.

OUR PORTFOLIO

View All

PRESS

Jun 9, 2026
Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors
Read More
Jun 7, 2026
Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a firstin- class GIPR antagonist
Read More
May 27, 2026
Cardiosense Receives FDA De Novo Classification for Novel Cardiac Technology Designed to Improve Care for Patients with Heart Failure
Read More
May 21, 2026
Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officer
Read More
View All